Mineralys Therapeutics (NASDAQ:MLYS) Sets New 1-Year Low - Should You Sell?

Mineralys Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Mineralys Therapeutics hit a new 52-week low, trading as low as $13.58; its latest reported price was $14.499, down sharply from its 50- and 200-day moving averages of $21.42 and $25.84.
  • Analyst views are mixed, with the stock carrying an overall “Hold” consensus and a $43.60 average price target. Recent ratings range from UBS’s $29 target to HC Wainwright’s $56 target.
  • The company missed quarterly earnings expectations, reporting a loss of $0.64 per share versus the $0.55 loss analysts expected. Insiders also sold about 189,758 shares worth $5.2 million in the last quarter.
  • MarketBeat previews top five stocks to own in December.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) hit a new 52-week low on Friday. The company traded as low as $13.58 and last traded at $14.4990, with a volume of 83,312 shares changing hands. The stock had previously closed at $14.16.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. UBS Group initiated coverage on shares of Mineralys Therapeutics in a report on Sunday, October 11th. They set a "neutral" rating and a $29.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $56.00 price target on shares of Mineralys Therapeutics in a research note on Monday, October 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Thursday, October 15th. Zacks Research upgraded Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Friday, September 11th. Finally, Wall Street Zen downgraded Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $43.60.

Read Our Latest Report on Mineralys Therapeutics

Mineralys Therapeutics Stock Performance

The firm has a market capitalization of $1.24 billion, a P/E ratio of -3.22 and a beta of 0.83. The company has a current ratio of 11.83, a quick ratio of 11.83 and a debt-to-equity ratio of 0.15. The business's 50 day simple moving average is $21.42 and its two-hundred day simple moving average is $25.84.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.09). Sell-side analysts anticipate that Mineralys Therapeutics, Inc. will post -4.64 EPS for the current fiscal year.

Insiders Place Their Bets

In other Mineralys Therapeutics news, insider Eric Warren sold 7,438 shares of Mineralys Therapeutics stock in a transaction on Monday, September 21st. The stock was sold at an average price of $28.12, for a total value of $209,156.56. Following the completion of the sale, the insider owned 38,400 shares of the company's stock, valued at approximately $1,079,808. This trade represents a 16.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian Slingsby sold 104,320 shares of Mineralys Therapeutics stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $28.81, for a total value of $3,005,459.20. Following the completion of the sale, the director directly owned 7,805,718 shares of the company's stock, valued at approximately $224,882,735.58. The trade was a 1.32% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 189,758 shares of company stock valued at $5,209,856. 18.94% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of hedge funds have recently bought and sold shares of MLYS. KBC Group NV purchased a new stake in shares of Mineralys Therapeutics during the 1st quarter valued at about $33,000. Sterling Capital Management LLC raised its holdings in shares of Mineralys Therapeutics by 902.0% during the third quarter. Sterling Capital Management LLC now owns 2,024 shares of the company's stock valued at $51,000 after purchasing an additional 1,822 shares during the last quarter. FNY Investment Advisers LLC lifted its position in Mineralys Therapeutics by 400.0% during the second quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company's stock valued at $67,000 after purchasing an additional 2,000 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Mineralys Therapeutics during the third quarter valued at approximately $114,000. Finally, Capstone Investment Advisors LLC bought a new position in Mineralys Therapeutics during the second quarter valued at approximately $226,000. Hedge funds and other institutional investors own 84.46% of the company's stock.

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular and kidney conditions associated with excess aldosterone. The company is based in Radnor, Pennsylvania, and was founded in 2019. Its lead product candidate, lorundrostat, is an investigational oral inhibitor of aldosterone synthase. Mineralys is studying the drug as a potential treatment for difficult-to-control hypertension and conditions related to excess aldosterone; it is not an approved or marketed therapy.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Mineralys Therapeutics Right Now?

Before you consider Mineralys Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.

While Mineralys Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines